Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype? by McNeish, Iain A.
 
 
 
 
 
McNeish, I. A. (2016) Prognostic pathways in early-stage ovarian cancer: 
can gene expression transcend histological subtype? Annals of Oncology, 
27(8), pp. 1366-1368. (doi:10.1093/annonc/mdw254)  
 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/132204/ 
     
 
 
 
 
 
 
Deposited on: 30 January 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Prognostic pathways in early stage ovarian cancer – can gene expression transcend 
histological subtype?  
 
Iain A McNeish 
 
Institute of Cancer Sciences, University of Glasgow, Glasgow UK 
 
 
Ovarian cancer, like many other solid malignancies, presents a paradox.  Things change, and yet 
they stay the same: our understanding of fundamental disease biology has improved dramatically 
in the past decade [1], yet the large majority of patients still present with advanced disease, and 
overall survival still remains poor [2].   
 
One critical change has been the realisation that ovarian cancer is a series of separate diseases, 
driven by distinct mutational processes [1].  The commonest histological subtype, high grade 
serous carcinoma, is marked by universal mutation in TP53 [3], chromosomal instability [4] and 
rapid dissemination around the peritoneal cavity, with many cases arising in the secretory cells of 
the distal fallopian tube rather than the ovary itself [5].  By contrast, clear cell and low-grade 
endometrioid carcinomas are TP53 wild-type but often contain mutations in ARID1A, a component 
of the SWI/SNF chromatin re-modelling complex [6], and PIK3CA [7].  Many mucinous ovarian 
cancers, with frequent KRAS mutations, represent metastases from gastrointestinal tumours [8, 9], 
whilst low grade serous carcinomas, arising on the background of borderline/low malignant 
potential tumours, harbour mutations in KRAS and BRAF [10].  Improved immunohistochemical 
analyses now allow for more accurate classification of tumours [11], and pathological re-
examination of archival specimens frequently leads to re-classification [12].  Critically, patterns of 
expression are consistent within anyone ovarian cancer subtype, and do not alter with stage [13].   
 
Gene expression studies have also been revealing.  Early array data indicated that the individual 
subtypes of ovarian cancer had very distinct patterns of gene expression [14, 15] that correlated 
with their different tissues of origin [16].  More recently, large consortium studies have indicated 
that, within cohorts of predominantly high grade serous tumours, there are distinct expression 
subgroups, with markedly different prognoses [4, 17].  Exactly how these gene expression 
subgroups link to specific mutation patterns, however, remains unclear. 
 
Only around 20% patients are diagnosed with stage I disease (confined to the ovary with or without 
cyst rupture and/or positive cytology in peritoneal washings).  Outcome for these patients is 
generally good, with 80% still alive five years following diagnosis [18].  Two large randomised 
trials, ICON1 and ACTION, indicated that there is a significant improvement in overall survival 
when platinum-based chemotherapy is given following initial surgery [19, 20].  This improvement 
remained after long-term follow up, although debate remains as to whether patients with low grade 
stage IA/B disease [21] and those who undergo extensive staging surgery [22] require adjuvant 
chemotherapy.  
 
It is against this background that Carula et al present their analysis of a series of stage I ovarian 
cancers [23].  Using frozen specimens collected at surgery between 1992 and 2011 in three large 
Italian centres, the authors analysed gene expression in stage I ovarian cancers of all histological 
subtypes, and describe a gene expression signature (ISC, the ‘Integrated Signature Classifier’) of 
26 individual genes and miRNA that defines a poor prognosis group.  The genes include those 
involved in cell cycle regulation (e.g. CCND1/2/3, CDK4/6), Hedgehog signalling (e.g. GLI1) and 
activin/inhibin signalling (e.g. ACVR1/2B).  Key miRNA included let-7e, miR-34a and miR-145.  
The original discovery sample set consisted of 34 tumours, 17 grade 1 and 17 grade 3.  Further 
refinement was performed on a training set of 157 tumours that also included the original 34 
discovery samples. An ISC score, ranging from 0 – 1, was given to each sample, depending upon 
how well the gene expression of that tumour correlated with the 26-gene poor prognosis signature.  
Separate Receiver Operating Characteristic (ROC) curves for progression-free and overall survival 
were used to define classifiers of high and low risk. Finally, these parameters were applied to a 
validation cohort of 46 tumours. 
 
Overall, this is an admirable piece of work – the authors have utilised large, well-annotated sample 
sets and have undertaken extensive analyses using methods that are clearly described, and raw 
expression data are publically available.  The results are simultaneously impressive and intriguing.  
Impressive because, in both univariate and multivariate analyses, the ISC classifiers were 
extremely powerful predictors of both progression-free and overall survival in the validation cohort.  
Intriguing because the authors appear to have identified patterns of gene expression that predict 
outcome across multiple histological subtypes that, as stated above, represent different diseases 
with distinct oncogenic drivers.  Moreover, the risk classifiers worked independently of 
chemotherapy treatment. 
 
There are some caveats and quirks in the analysis that cannot be ignored.  The samples were 
collected over a 20 year period and were not subject to full pathological review using current 
methodology and consistent diagnostic criteria.  Patients were also not managed with uniform 
chemotherapy protocols or follow up schedules, so progression-free survival data will be less 
robust than in a prospective clinical trial. It is not clear whether all patients underwent optimal 
staging as defined by Trimbos et al in the ACTION study [22]. Sample set B is stated to harbour no 
TP53 mutations yet contains 32 high grade serous tumours, where TP53 mutations are universal 
[3, 24].  There is also some circularity in the sample utilisation and analysis – all 34 discovery 
samples were re-analysed in the test set, whilst the decision to use grade (1 vs 3) to define 
prognostic gene expression signatures was partially based upon an initial multivariate analysis of 
all 203 tumours in the discovery, test and validation cohorts. 
 
Despite these reservations, the data are impressive and do suggest that there are patterns of gene 
expression that are prognostically important.  The presence of cell cycle genes in the ISC is 
perhaps not unexpected – in ovarian high grade serous tumours, amplification of CCNE1 is a poor 
prognosis feature, associated with primary platinum resistance [25], whilst CCNE1 amplification 
and increased CCND1 expression are both negative features in breast cancer [26, 27], suggesting 
that aberrant G1/S checkpoint control is a general poor prognostic marker.  Similarly, there are 
data to suggest that Hedgehog signalling is a marker of poor outcome across multiple tumours [28-
30].  Data on activin/inhibin signalling are sparser, but again results suggest that upregulation of 
this pathway is a poor prognosis feature in other malignancies [31, 32].  Thus, there do appear to 
be certain pathways that are universal markers of poor outcome.  It would be interesting to see if 
the ISC signature applies to more advanced ovarian cancer, and the availability of large publically 
available data sets such as TCGA would make such an analysis relatively simple.  Certainly, 
further validation in an entirely independent sample set of early ovarian cancers would be most 
reassuring.   
 
The critical question is how to utilise these data.  Do we yet have confidence to apply the ISC 
prospectively, to recommend no chemotherapy to some women with early stage disease who 
would currently be offered platinum?  The answer must be ‘not yet’.  However, the ability to simplify 
gene expression assessment using platforms such as Nanostring and Taqman [33] means that 
rapid and sensitive assessment for prospective stratification in clinical trials is imminent. 
 
Overall, the results remind us that, although classification of tumours based upon DNA mutations 
is extremely important, gene expression analyses remain vital and can provide valuable 
information that will ultimately be utilised to guide treatment decisions. 
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